DeepakCyrilD'SouzaMD

Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director, Neurobiological Studies Unit, VACHS; Director, VA-CMHC Schizophrenia Research Clinic

Join to view full profile

Are you Dr. D'Souza?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 35 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
950 Campbell Ave
Psychiatry Svc 116a, Va Connecticut Healthcare System
West Haven, CT 06516
Phone+1 203-932-5711

Fax+1 203-937-4860

Summary

Dr. Deepak D'Souza, MD is a board certified psychiatrist in West Haven, Connecticut. He is currently licensed to practice medicine in Connecticut. He is affiliated with Veterans Affairs Connecticut Healthcare System and is a Professor of Psychiatry; Director Schizophrenia Neuropharmacology Research Group at Yale (SNRGY); Director at VACHS; Director.

Education & Training

SUNY Downstate Health Sciences UniversityResidency, Psychiatry, 1988 - 1992
St. John's Medical CollegeClass of 1986

Certifications & Licensure

CT State Medical License 1993 - 2026
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia Start of enrollment: 2002 Sep 01
Completed
Phase 3
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia Start of enrollment: 2005 Feb 01
Completed
Phase 3
Interactive Psychopharmacologic Effects of Alcohol and Nicotine in Humans Start of enrollment: 2007 Jan 01
Completed
Early Phase 1
Cannabinoid Receptor Function & Alcoholism Start of enrollment: 2007 Aug 09
Completed
Phase 1
Pharmacogenetics of Cannabinoid Response Start of enrollment: 2007 Aug 23
Completed
Early Phase 1
Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects Start of enrollment: 2002 Dec 01
Completed
Phase 1
Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects Start of enrollment: 2008 Jan 22
Completed
Phase 1
Cannabinoids, Neural Synchrony, and Information Processing Start of enrollment: 2008 Feb 25
Completed
Early Phase 1
Effects of Delta-9-THC and Iomazenil in Healthy Humans Start of enrollment: 2009 Feb 11
Completed
Early Phase 1
Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone Start of enrollment: 2010 Jul 01
Completed
Phase 3
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans Start of enrollment: 2012 Dec 14
Active, not recruiting
Phase 1
The Effects of ∆-9-THC and Naloxone in Humans Start of enrollment: 2011 Nov 04
Completed
Early Phase 1
Cannabinoid Modulation of Pain Start of enrollment: 2011 Nov 09
Completed
Early Phase 1
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal Start of enrollment: 2012 Sep 12
Completed
Phase 2
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning Start of enrollment: 2010 Jul 01
Recruiting
Translational Neuroscience Optimization of GlyT1 Inhibitor Start of enrollment: 2013 Aug 01
Completed
Phase 2
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD) Start of enrollment: 2019 Jan 14
Completed
Phase 2
CB1R in Synthetic Psychoactive Cannabinoids Start of enrollment: 2018 May 01
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

3 citations
Letter to the Editor: Cannabis as a Solution to the Opioid Crisis: Is the Cart Before the Horse Again?
Joao P De Aquino, Anees Bahji, Deepak Cyril D'Souza
Cannabis and Cannabinoid Research. 2021-10-28
5 citations
Assessment of transient dopamine responses to smoked cannabis.
Katina C. Calakos, Heather Liu, Yihuan Lu, Jon Mikael Anderson, David Matuskey
Drug and Alcohol Dependence. 2021-10-01
21 citations
Cannabis and Driving
Godfrey D. Pearlson, Michael C. Stevens, Deepak Cyril D'Souza
Frontiers in Psychiatry. 2021-09-24

Press Mentions

California May Require Labels on Pot Products to Warn of Mental Health RisksJune 17th, 2022
Scarce Evidence Backing Cannabinoids for Psych DisordersOctober 28th, 2019
There's No Evidence Marijuana Will Treat Your Anxiety or DepressionOctober 28th, 2019

Grant Support

Imaging Brain Cannabinoid Receptors (CB1) In SchizophreniaNational Institute Of Mental Health2012
Imaging Brain Cannabinoid Receptors In Cannabis Dependence, Withdrawal And AbstinNational Institute On Drug Abuse2011
Cannabidiol Modulation Of ???-9-Thc???S Psychotomimetic Effects In Healthy HumansNational Institute On Drug Abuse2011
Imaging Nicotinic Acetylcholine Receptors In SchizophreniaNational Institute On Drug Abuse2009–2011
GABA Deficits And Vulnerability To Cannabinoid-Induced PsychosisNational Institute Of Mental Health2009–2010
Neurobiology Of Cannabis EffectsNational Institute On Drug Abuse2007–2009
Cannabinoids, Neural Synchrony And Information ProcessingNational Institute On Drug Abuse2007–2008
Cannabinoid Receptor Function In Alcoholism: Effects Of D-9-ThcNational Institute On Alcohol Abuse And Alcoholism2007–2008
Neurobiology Of Cannabis Behavioral EffectsNational Institute On Drug Abuse2001–2003
Glycine-Ketamine Interactions In Healthy SubjectsNational Institute Of Mental Health2000–2002
Effects In Schizophrenics Versus Healthy Controls.National Institute On Alcohol Abuse And Alcoholism1998–1999